Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biotechnology
Cygnal Therapeutics launches with $65 million in funding
by Megha Satyanarayana
October 12, 2019
| A version of this story appeared in
Volume 97, Issue 40
Cygnal Therapeutics has emerged from stealth mode with $65 million in funding, mostly from the venture capital firm Flagship Pioneering. The Cambridge, Massachusetts–based biotech firm focuses on exoneurobiology, the neurobiology of the peripheral nervous system. CEO Pearl Huang says nerves outside the central nervous system play a significant role in disease and that Cygnal’s multifaceted platform will allow it to find small molecules and build biologics that affect the activity of these nerves.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter